ADC Therapeutics SA — Form 6-K Summary
Business context and reporting period
ADC Therapeutics SA filed a Form 6-K for July 2022, dated July 11, 2022. On July 8, 2022, the company entered into a license agreement with Swedish Orphan Biovitrum AB (Sobi) for development and commercialization of ZYNLONTA outside the United States, greater China, Singapore and Japan.
Key transaction economics
| Item | Terms |
|---|---|
| Upfront payment | $55 million |
| Potential milestones | Up to $382.5 million in regulatory and net sales-based milestones, including $50 million upon European Commission approval of an MAA for third-line DLBCL |
| Royalties | Tiered royalties ranging from the mid-teens to the mid-twenties on net sales in the covered territory |
| Clinical-study cost sharing | Sobi will co-fund 25% of certain specified global clinical studies, with an option to co-fund additional studies subject to an aggregate annual cap of $10 million |
The filing does not provide revenue, profit, cash flow, margin, debt or liquidity figures, and it does not state the accounting treatment or timing of recognition for the upfront payment or contingent consideration.
Material changes and operating responsibilities
- Sobi receives an exclusive license to develop, sell, distribute, import and commercialize ZYNLONTA in the covered territory, with specified non-exclusive rights for packaging, labeling and potential manufacturing.
- Sobi will conduct and fund development and commercialization activities in the covered territory, except for specified global clinical-study costs.
- ADC Therapeutics retains rights specified in the agreement and continues to control territories outside the covered territory.
- The parties agreed to restrictions on developing or commercializing competing CD19 products for DLBCL in the covered territory, subject to exceptions for acquisitions involving competing programs and required firewalls.
Outlook, risks and contingencies
- Milestone payments depend on regulatory approvals and net sales and are not guaranteed.
- Royalties may be reduced in specified circumstances, including patent expiration, generic or biosimilar competition and required third-party payments.
- Royalty terms generally extend to the latest of 10 years after first commercial sale in a country, expiration of the last valid applicable patent claim, or expiration of regulatory exclusivity.
- Sobi may terminate the agreement at its discretion with 180 days’ notice and may terminate for safety reasons. Either party may terminate for uncured material breach or insolvency, and ADC Therapeutics may terminate in connection with certain patent challenges by Sobi.
- The agreement generally continues until expiration of the last royalty term for the last product in the last covered-territory country, unless terminated earlier.
- After a product’s royalty term expires in a country, Sobi’s licenses become non-exclusive, fully paid, royalty-free, perpetual and irrevocable for that product and country.
Important facts for investors to verify
- Whether and when the $55 million upfront payment was received and recognized under applicable accounting standards.
- The company’s subsequent disclosures regarding European regulatory progress and the potential $50 million MAA approval milestone.
- The full license agreement, including retained rights, sublicensing provisions, termination rights and detailed milestone conditions.
- Any later disclosures regarding global clinical-study costs, Sobi’s co-funding, ZYNLONTA sales and royalty income.
- The company’s cash balance, liquidity runway, debt and operating results in its next financial filing, as these are not included in this Form 6-K.